Joe Palca

Joe Palca is a science correspondent for NPR. Since joining NPR in 1992, Palca has covered a range of science topics — everything from biomedical research to astronomy. He is currently focused on the eponymous series, "Joe's Big Idea." Stories in the series explore the minds and motivations of scientists and inventors. Palca is also the founder of NPR Scicommers – A science communication collective.

Palca began his journalism career in television in 1982, working as a health producer for the CBS affiliate in Washington, DC. In 1986, he left television for a seven-year stint as a print journalist, first as the Washington news editor for Nature, and then as a senior correspondent for Science Magazine.

In October 2009, Palca took a six-month leave from NPR to become science writer in residence at The Huntington Library, Art Collections, and Botanical Gardens.

Palca has won numerous awards, including the National Academies Communications Award, the Science-in-Society Award of the National Association of Science Writers, the American Chemical Society's James T. Grady-James H. Stack Award for Interpreting Chemistry for the Public, the American Association for the Advancement of Science Journalism Prize, and the Victor Cohn Prize for Excellence in Medical Writing. In 2019, Palca was elected to the American Academy of Arts and Sciences for outstanding achievement in journalism.

With Flora Lichtman, Palca is the co-author of Annoying: The Science of What Bugs Us (Wiley, 2011).

He comes to journalism from a science background, having received a Ph.D. in psychology from the University of California at Santa Cruz, where he worked on human sleep physiology.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

NOEL KING, HOST:

A panel of experts convened by the National Institute of Allergy and Infectious Diseases recommends against doctors using a combination of hydroxychloroquine and azithromycin for the treatment of COVID-19 patients because of potential toxicities.

"The combination of hydroxychloroquine and azithromycin was associated with QTc prolongation in patients with COVID-19," the panel said.

QTc prolongation increases the risk of sudden cardiac death.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

STEVE INSKEEP, HOST:

Being able to test for coronavirus infections is a critical component to reopening society — even a little bit — after the initial wave of COVID-19. So there is an urgent need for faster, cheaper tests than the ones available at present.

Two of the world's largest vaccine manufacturers are joining forces to develop a new vaccine to prevent COVID-19.

Usually, the pharmaceutical behemoths GlaxoSmithKline and Sanofi are competitors, but in a conference call with reporters, GSK CEO Emma Walmsley said the coronavirus pandemic represented "an unprecedented global health threat," and, therefore, required new ways of doing business.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

Gilead Sciences is reporting some preliminary results from the use of its antiviral drug remdesivir in treating patients with COVID-19.

The study, published Friday by the New England Journal of Medicine, evaluated the response of 53 patients given remdesivir on a compassionate use basis.

Thirty-six showed clinical improvement, while eight got worse. Patients who were not on a ventilator tended to do better than those who were. Seven of the 53 died.

How do you know when an experimental drug is working? For scientists, that answer only comes from carefully controlled clinical trials.

For President Trump, such trials aren't something he wants to wait on before promoting such a drug.

At Tuesday's White House coronavirus task force briefing, Trump told the story of a woman from Michigan who was sick with COVID-19 — a story he had seen on television the night before.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

President Trump asked Americans during Monday's coronavirus briefing to maintain their social distancing through the end of the month to bring the coronavirus under control.

And if people really do observe the stay-at-home orders, models suggest that the epidemic could wane by summer. There's also hope that the changing weather will help slow the spread of the virus, though that's far from certain.

But there's a problem. Even if things "get better all of a sudden," as the president suggested he hoped would happen, the virus will not have gone away.

Updated at 2:20 p.m. ET

The Food and Drug Administration announced Friday it was taking the lead on a national effort to facilitate the use of plasma from recovered patients to treat patients infected with the coronavirus.

The FDA program involves the Mayo Clinic and the American Red Cross, with funding from the federal government's Biomedical Advanced Research and Development Authority.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

AILSA CHANG, HOST:

A nationwide trial is underway to see if the drug hydroxychloroquine can prevent disease in people exposed to the novel coronavirus. A second trial will test to see if the drug can prevent severe disease in people who are already showing COVID-19 symptoms.

The trials are being run by David Boulware, an infectious disease scientist at the University of Minnesota.

"My normal research is doing clinical trials in Africa for fungal meningitis of the brain," Boulware says.

When our bodies are invaded by a virus, our immune systems make particular proteins called antibodies to help fight off infection.

Scientists working to quell the COVID-19 pandemic think it will be possible to figure out which antibodies are most potent in quashing a coronavirus infection, and then make vast quantities of identical copies of these proteins synthetically.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

AILSA CHANG, HOST:

The federal government is now adding supercomputers to its tool set in the hunt for ways to stop COVID-19.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

MICHEL MARTIN, HOST:

While health officials in the United States wait to see just how bad a public health challenge COVID-19 will pose, they still have to deal with an all-too-familiar challenge: flu.

It's been a bad flu season. Not the worst ever, but bad.

"It started very early this year," says Emily Martin, associate professor of epidemiology at the University of Michigan School of Public Health. She works with the Centers for Disease Control and Prevention collecting statistics about flu.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

MICHEL MARTIN, HOST:

RACHEL MARTIN, HOST:

You want to stop the spread of coronavirus? You got to keep health workers safe. That means giving them the protective gear they need, including something called a respirator, which protects someone from breathing in viral particles. NPR science correspondent Joe Palca traveled to the 3M mask manufacturer in Minnesota.

JOE PALCA, BYLINE: At 3M, they've been thinking about how to respond to the coronavirus outbreak for a while.

NIKKI MCCULLOUGH: In mid-January, we started to notice some strange disease patterns coming out of China.

Viral infections can be very hard to treat. Just ask anyone who has a bad case of the flu.

But that's not deterring research groups around the world from looking for an effective therapy against the new coronavirus, although they know it won't be easy.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

ARI SHAPIRO, HOST:

RACHEL MARTIN, HOST:

More disturbing numbers about the coronavirus. Today, China's National Health Commission disclosed that 1,700 medical workers are among those who've contracted the disease, which is now known as COVID-19. Six of those workers have died. They're among the more than 5,000 new coronavirus cases reported in just the past 24 hours. Labs all over the world are racing to design diagnostic tests, vaccines, new therapies all to deal with the virus. NPR's Joe Palca is here to talk about a promising pilot program happening here in the U.S. Hi, Joe.

Right now scientists are trying to accomplish something that was inconceivable a decade ago: create a vaccine against a previously unknown virus rapidly enough to help end an outbreak of that virus. In this case, they're trying to stop the spread of the new coronavirus that has already infected tens of thousands of people, mainly in China, and given rise to a respiratory condition now known as COVID-19.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

MARY LOUISE KELLY, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

AILSA CHANG, HOST:

It's not easy to treat viral infections. Just ask anyone with a bad cold or a case of the flu.

But scientists in Massachusetts think they may have a new way to stop viruses from making people sick by using what amounts to a pair of molecular scissors, known as CRISPR.

It's a gene editing tool based on a molecule that occurs naturally in microorganisms.

Pages